Skip to main content

Fiscal Wizard · Single-issue tearsheet

NBIX / Jun 21, 2026 Run #7378

NBIX

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Composite verdict

A 75.9 / 100
Bullish setup · Reversal 12 drivers · 3 gates blocking
  • Volume Climax
  • Relative Strength vs SPY
  • Aroon Oscillator
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 3rd of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 17 signals0% Bear
Momentum Bullish 98Mean-reversion Neutral 52

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -68%
Asset value $32.35Earnings power value $49.38Price $158.29

Priced above its no-growth earnings power value ($49.38/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

51.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 86
OCF to Net Income 0
PEG 81
Earnings Yield 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Volume Climax, Relative Strength vs SPY, Williams %R); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Volume Climax 86
Relative Strength vs SPY 84
Aroon Oscillator 81

Risk Gates

3 blocking 5 caution

3 guards active, 24 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NBIX.